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Streptococcus pneumoniae is the most frequent cause of community-acquired
pneumonia. Endogenous host defense molecules such as peptidoglycan recognition
protein 4 (PGLYRP4) might influence the course of this disease. To the best of our
knowledge, there are no reports on the relevance of PGLYRP4 in pneumonia. Therefore,
wild type (WT) and PGLYRP4-deficient (PGLYRP4KO) mice were analyzed in an in vivo
and in vitro experimental setting to examine the influence of PGLYRP4 on the course
of pneumococcal pneumonia. Furthermore, caecal 16S rRNA microbiome analysis was
performed, and microbiota were transferred to germfree WT mice to assess the influence
of microbiotal communities on the bacterial burden. Mice lacking PGLYRP4 displayed
an enhanced bacterial clearance in the lungs, and fewer mice developed bacteremia.
In addition, an increased recruitment of immune cells to the site of infection, and
an enhanced bacterial killing by stronger activation of phagocytes could be shown.
This may depend partly on the detected higher expression of complement factors,
interferon-associated genes, and the higher pro-inflammatory cytokine response in
isolated primary PGLYRP4KO vs. WT cells. This phenotype is underlined by changes
in the complexity and composition of the caecal microbiota of PGLYRP4KO compared
to WT mice. Strikingly, we provided evidence, by cohousing and stable transfer of the
respective WT or PGLYRP4KOmice microbiota into germfree WTmice, that the changes
of the microbiota are responsible for the improved clearance of S. pneumoniae lung
infection. In conclusion, the deficiency of PGLYRP4, a known antibacterial protein, leads
to changes in the gut microbiota. Thus, alterations in the microbiota can change the
susceptibility to S. pneumoniae lung infection independently of the host genotype.
Keywords: infectious diseases, innate immunity, microbiome, peptidoglycan recognition proteins (PGRP,
PGLYRP), pneumococcal pneumonia, Streptococcus pneumoniae
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INTRODUCTION
Streptococcus pneumoniae (S. pneumoniae) was discovered in the
late nineteenth century (1) as a major course of pneumonia.
It kills 1.5–2 million people every year with the highest rates
in children younger than five and adults older than 65 years
of age (2, 3). Thus, S. pneumoniae is one of the major causes
of death worldwide. The global increase of antibiotic resistant
S. pneumoniae strains (4), and escape strategies to vaccination
via serotype-switch (5) underline the necessity to develop new
treatment strategies.
Host defense molecules (HDMs) such as defensins,
cathelicidine LL-37, and peptidoglycan recognition
proteins (PGRPs/PGLYRPs) were shown to have not only
direct antimicrobial activity, but often also act in an
immunomodulatory fashion (6). PGRPs were first isolated
in 1996 from the silkworm Bombyx mori (7) and mice (8). Now,
about a hundred PGRPs have been identified (9, 10). For the
purpose of distinction, mammalian PGRPs have been termed
as PGLYRPs and numbered from 1 to 4. They have either an
N-acetylmuramyl-alanine amidase activity (PGLYRP2), or are
described to have antibacterial properties (PGLYRP1-4) against
a range of gram-positive and gram-negative bacteria (10–14).
Furthermore, several groups reported immunomodulatory
functions including chemoattractant and cytotoxic properties,
antitumor effects, regulation of pro-inflammatory cytokine
response in chemical-induced inflammation models, and
influence on the recruitment of PMNs (15–20). PGLYRP4
especially is known for its regulation on the Treg/Th17 balance
and anti-inflammatory properties in atopic dermatitis and
chemical-induced colitis (18). PGLYRP4 is mainly expressed
in epithelial cells of the esophagus, skin, and intestine (10).
Furthermore, there are also reports of a regulatory role of
PGLYRP4 on healthy gut microbiota (19, 21).
Themicrobiota is considered to include all microbes (bacteria,
archaea, viruses, fungi, and protozoa) associated with and within
the organism (22). Interaction between host and the microbiota
is an important factor for the host’s health. Shifts or imbalances
of the microbiota, also called dysbiosis, can be followed by
pathogenic bacteria outgrowing the commensals, and ultimately
promoting or even causing diseases (23, 24).
Increasing number of reports highlight the influence of the
gut microbiota on lung diseases. Thus, the so-called gut-lung
axis has become an important topic in microbiota research in
the last few decades. Current research indicates an important
role of the gut microbiota in the defense against lung infections
such as bacterial pneumonia (25), or have linked chronic
obstructive pulmonary disease (COPD) to Crohn’s disease (26).
Such effects could be mediated, at least partly, by bacterial
metabolites like short-chain fatty acids (SCFAs), which can have
systemic immunomodulatory effects by migration via the blood
stream (27).
To analyze the so far unknown effects of PGLYRP4 on
lung infections, and investigate possible gut-lung immune
interactions, we investigated the influence of PGLYRP4-
deficiency on the development and outcome of pneumococcal
pneumonia. Therefore, we transnasally infected WT and
PGLYRP4KO mice with S. pneumoniae. Unexpectedly, we found
a lower bacterial burden in the lungs and blood of infected
PGLYRP4KO vs. WT mice, which was accompanied by higher
inflammation, and enhanced bacterial killing by phagocytes.
Cohousing experiments confirmed that these effects are at least




All mice were on a BALB/c background, bred and housed at
the central breeding facility of the Charité – Universitätsmedizin
Berlin (Forschungseinrichtung für Experimentelle Medizin,
FEM). Breeding pairs for the WT and PGLYRP4KO mice were
kindly provided by Prof. Dr. Roman Dziarski (Department of
Microbiology and Immunology, Indiana University School of
Medicine, Indiana, USA) who originally obtained the mice from
Harlan-Sprague-Dawley and generated the PGLYRP4KO mice
as described by Saha et al. (19). Germ-free BALB/c WT mice
were obtained from the central animal facility of the Medical
University of Hannover.
Housing Conditions
Animals were kept at a 12 h light/dark cycle, with food and
water ad libitum. All animal procedures were in compliance
with the Federation of European Laboratory Animal Science
Associations (FELASA) guidelines and recommendations for
the care and use of laboratory animals, and were approved
by local institutional (Charité – Universitätsmedizin Berlin)
and governmental (LAGeSo Berlin, approval ID: G0251/12 and
G0266/15) authorities.
PGLYRP4KO mice were routinely genotyped to ensure that
they were homozygous for the knockout. We did not use
heterozygous WT and KO littermates because the effect of the
PGLYRPs on the composition of the microbiota takes a long time
to stabilize, which is only possible with homozygous breeding
[described earlier in Dziarski et al. (21)].
It is known that housing conditions such as diet, stress, type
of caging, and other environmental factors have an impact on
the gut microbiome (28, 29). Therefore, PGLYRP4KO and WT
mice were bred and housed in the same conventional pathogen-
free room of our facility with the same environment setting to
avoid differences in the microbiota by variations in the housing
conditions. Individually ventilated cages, nesting material,
enrichment, food and water were autoclaved. Furthermore, all
experiments were done with animals from several breeding
pairs to avoid analyzing selective microbiota from only one
maternal lineage or cage and to increase biological plausibility by
increased diversity.
Additional Information
PGLYRP4KO and respective control WT mice were always
infected together to exclude differences due to infection time,
dose, or bacteria. In accordance to the 3R principles we reduced
the amount of animals by using some of the WT mice also in
another study with PGLYRP3-deficent mice (30). These include
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11 WT animals in Figures 1A–D, 7A–C,E, 15 WT mice in
Figures 1E, 7D, and three WT mice in Figure 2A. Thereby, we
reduced the number of animals used in these studies to the
minimum amount.
Genotyping PCR
Tail tips were used for the isolation of DNA. After incubation
over night at 54◦C in tail lysis buffer (0.1M Tris, 5mM EDTA,
200mM NaCl, 0.2% SDS, 10 mg/ml Proteinase K), the samples
were then centrifuged (4,000 × g, 10min, RT). The DNA was
extracted from the supernatant with isopropanol, washed twice
with 70% ethanol, air dried, and dissolved in nuclease-free water
(56◦C, 30 min).
The PCR was performed using 50 ng of purified DNA, 0.1mM
dNTPs, 0.1µM of each forward and reverse primer, and 1.25U
DreamTaq DNA Polymerase. Primers were as follows: Forward
primer either WT: GCACTCTAGTCCAGGGATATGGTG
or PGLYRP4KO: AGCGCATCGCCTTCTATCGCCTTC and
reverse primer GTCAGTGTCTCTCCTAGGGTTGC (TIB
MOLBIOL GmbH, Berlin, Germany). The cycling conditions
were: 3min at 95◦C, 30 cycles with 30 s at 95◦C, 30 s at 64◦C
and 2min at 72◦C, plus a final step for 7min at 72◦C. After
amplification, PCR products were run on a 1% agarose gel
(Promega, Mannheim, Germany) with 0.04% ethidium bromide
(Invitrogen, Massachusetts, USA), and visualized under UV-light
to detect the amplicons.
Mouse Infection
Infection Model
For the in vivo experiments, female BALB/c mice (9–12 weeks)
were used. After anesthesia with i.p. injection of ketamine
and xylazine (both Rotexmedica, Luitré, France), mice were
inoculated transnasally with 20 µl of bacterial suspension of S.
pneumoniae serotype three strain (NCTC 7978) or 20µl of sterile
PBS as a control (30).
Monitoring
During the experiments, the mice were monitored every 12 h to
assess clinical signs of illness Humane endpoints were defined as
(i) body weight loss ≥ 20%, (ii) cumbersome breathing, and (iii)
accelerated breathing or hypothermia (<30◦C) in combination
with staggering or pain. No mice reached the predefined humane
endpoints before the end of the experiments.
Scoring of Clinical Signs
The following 11 symptoms were scored: disheveled fur, crusty
secretion on the eye rim, reduced reaction or movement,
isolation, temperature ≤ 35.0◦C, body weight loss ≥ 10%,
body weight loss ≥ 20%, body weight loss ≥ 25%, accelerated
breathing, cumbersome breathing, pain. Scoring was performed
according to their presence or not (1 or 0, respectively) with the
exemption of disheveled fur, which was scored according to its
severity (0, 0.5, 1, 1.5, or 2) and the sum was calculated. For
statistical purpose, 1 was added to the sum of the scores to result
in a final score ranging from 1 (minimum) to 12 (maximum).
Bacterial Strains
NCTC 7978 (A66) and NCTC 7466 (D39) were plated on
Columbia agar plates with 5% sheep blood and incubated
overnight (37◦C, 5% CO2). Single colonies were inoculated in
Todd-Hewitt broth, 0.5% yeast extract (both BD Biosciences,
Heidelberg, Germany), and 10% heat-inactivated FCS. After
incubation (37◦C, 5% CO2) until the mid-logarithmic growth
phase, the bacteria were centrifuged (1,800 × g, 10min) and the
bacterial pellet was resuspended in cell culture medium (in vitro
stimulations) or in sterile PBS (in vivo infections) in appropriate
concentration (30).
Bacterial Load
Serial dilutions of lung and spleen homogenates or EDTA-blood
from the in vivo experiments were plated on Columbia agar
with 5% sheep blood and incubated overnight (37◦C, 5% CO2).
Colonies were counted manually, and the bacterial load as colony
forming units (cfu) was calculated.
Cohousing Experiment
For microbiota transfer, 3–4-week-old female WT or
PGLYRP4KO mice were cohoused with female germ-free
WT mice at a ratio 1:1 with 2–6 mice per cage until an age of
9-10 weeks. Cages were changed weekly under an UV irradiated
laminar flow bench, and all materials including food and water
were autoclaved for sterility.
Isolation of Primary Cells
Untreated BALB/c WT and PGLYRP4KO mice (male, age 10–
16 weeks) were anesthetized i.p. with ketamine and xylazine
and exsanguinated by opening the vena cava caudalis. For the
isolation of AECs heparin (Rotexmedica, Luitré, France) was
included in the anesthesia mix.
Isolation of Alveolar Epithelial Cells (AECs)
The lungs were perfused via the heart with PBS, instilled with
5,000U of Dispase (BD Biosciences, Heidelberg, Germany), and
low melt agar (Invitrogen, Massachusetts, USA) as described
previously with some modifications (31). After incubation
in Dispase (6min, 37◦C), the lungs were macerated and
homogenized by passing through cell strainers (100, 70, and
30µm). The cell suspension was centrifuged (200 × g, 10min,
4◦C) and resuspended in PBS (3% FCS, 10 mM EDTA).
The AECs were isolated via negative selection with the
following antibodies: CD45, CD31, CD16/32, all biotinylated
(BD Biosciences, Heidelberg, Germany) using the MACS
procedure according to manufacturer’s instructions (Miltenyi
Biotec GmbH; Telterow, Germany). The purified AECs were
centrifuged (200 × g, 10min, 4◦C), resuspended in DMEM (1%
P/S, 1% Glu, 25mM HEPES, 10% FCS), seeded into cell culture
plates, and incubated (37◦C, 5% CO2, overnight). The next day,
medium was changed to DMEM with 2% FCS and 1% Glu and
the cells were infected 2 h later.
Isolation of Alveolar Macrophages (AM8s)
Alveolar macrophages were isolated from bronchoalveolar lavage
fluid as described (31). The AM8s were incubated (37◦C, 2 h)
in cell culture plates and medium (RPMI 1640, 10% FCS, 1%
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P/S, 1% Glu) was changed to remove non-adherent cells. After
overnight incubation (37◦C, 5% CO2) the medium was changed
to RPMI 1640 with 2% FCS and 1% Glu and the cells were
infected 2 h later.
Isolation of Neutrophils (PMNs)
Cells were flushed out from the femurs and tibiae with sterile
PBS, and PMNs were isolated via positive selection using the
MACS mouse Anti-Ly-6G Microbead kit (Miltenyi Biotech,
Bergisch Gladbach, Germany) according to the manufacturer’s
instructions. The isolated neutrophils were resuspended in RPMI
1640 with 2% FCS, 1% Glu and stimulated immediately.
Quantitative Real-Time PCR (qPCR)
For RNA isolation from primary BALB/c WT, AECs,
AM8s, and PMNs the TRIzol method was used. Total
RNA (1 µg) was transcribed into cDNA (High-Capacity
cDNA Reverse Transcription Kit), pre-amplified (TaqMan
PreAmp Master Mix Kit), and used for qPCR (TaqMan
Gene Expression Master Mix and TaqMan Assay Sequence
Numbers: Gapdh Mm99999915_g1, Pglyrp4 Mm01220032_m1,
Cldn18 Mm00517321_m1, F11r Mm00554113_m1,
Cdh1 Mm01247357_m1, C3 Mm01232779_m1, Ifng
Mm01168134_m1, Ifngr1 Mm00599890_m1; all Life
Technologies GmbH, Darmstadt, Germany). The qPCR
was performed according to the manufacturer’s instructions.
Cycling conditions: 2min, 50◦C, 10min, 95◦C, and 40 cycles
with 15 s, 95◦C and 1min, 60◦C. Relative expression was
calculated by the efficiency corrected 11Ct method (32) with
Gapdh as a housekeeping gene, and uninfected WT cells as an
untreated control.
Cytokine Measurement
Cell-free supernatants were used to measure the cytokines from
cultured primary WT and PGLRP4KO mouse cells (AECs,
AM8s, and PMNs). All ELISAs were performed according to the
manufacturer’s instructions (KC from R&D Systems, Abingdon,
UK; all others from eBioscience, Frankfurt am Main, Germany).
Values were adjusted to the mean of infected WT cells.
Microarray
Primary WT and PGLYRP4KO AM8s and AECs were cultured,
infected, and RNA was extracted as described above. For the
AM8s, RNA of three independent experiments were sent to
Source BioScience imaGene (Berlin, Germany) for analysis on an
Affimetrix GeneChip Mouse Gene 2.0 ST Array. For AECs, three
independent experiments were pooled. Analysis was performed
as described (33, 34) on an Agilent SurePrint G3 ∗ Mouse ∗ Gene
Expression 8x60K v2 Microarray with 200 ng RNA per sample.
Histology of the Lung
Mice were anesthetized i.p. with ketamine and xylazine, and
heparinized before exsanguination. Whole lungs including
tracheas were removed after ligation of the trachea to prevent
alveolar collapse, and immediately immersion-fixed in 4%
buffered formalin (Sigma-Aldrich, Darmstadt, Germany) at pH 7
for up to 48 h. Afterwards, lungs were embedded in paraffin and
cut into 2 µm sections.
For histopathology and immunohistochemistry (IHC) for the
identification of immune cell populations, sections were dewaxed
in xylene, rehydrated in decreasing ethanol concentrations,
and stained with hematoxylin and eosin (HE), anti-CD68
(ab125212, abcam, Cambridge, UK), anti-CD45R (RA3-6B2, BD
Biosciences, Heidelberg, Germany), anti-CD3 (A 452, DAKO,
Glostrup, Denmark), or anti-NE (ab68672, abcam, Cambridge,
UK) as described (35). IHC slides were counterstained with
hemalaun, and all slides were dehydrated through graded
ethanols, cleared in xylene, and coverslipped.
The stained lung slides were digitalized by an Aperio CS2
(Leica Biosystems Imaging Inc., Vista, CA, USA) pathology
scanner for subsequent digital image analyses (35). An adapted
Aperio GENIE histology pattern recognition algorithm (Leica
Biosystems Imaging Inc.) was used for the determination of
the affected lung areas, and the Aperio v9 nc algorithm (Leica
Biosytems Imaging Inc.) was employed for the quantification of
total numbers of nuclei or cells stained by IHC (35).
Cfu Assay
Untreated WT and PGLYRP4KO PMNs or PMNs pretreated
with supernatants (cell- and bacteria-free) from S. pneumoniae-
stimulated WT and PGLYRP4KO AECs were used for cfu assay.
Pneumococci were opsonized by incubation with mouse serum
(for WT PMNs with serum from WT mice and for PLYRP4KO
PMNs with serum from PGLYRP4KO mice) for 1 h at 37◦C and
then added to the PMNs. Infection was done with 106 cfu/ml
D39 for 1 h. The cells were lysed with Triton X-100 in HBBS
Ca2+/Mg2+, serial dilutions were plated on Columbia agar plates
with 5% sheep blood, and incubated overnight (37◦C, 5% CO2).
The next day colonies were counted and cfu’s were calculated.
Microbiota Analysis
Sample Preparation
All microbiota analysis experiments were done under a laminar
flow bench, and instruments as well as the bench were UV-
irradiated for 30min. The mice were anesthetized i.p. with
ketamine and xylazine and euthanized by cutting the vena
cava caudalis as described above. Samples were put in samples
tubes (Biosphere SafeSeal tubes, Sarstedt), snap frozen in liquid
nitrogen and stored at−80◦C until further processing. After each
mouse, instruments were cleaned by rinsing them with distilled
water and 70% ethanol. Appropriate control samples were taken
the same way.
DNA Extraction
Microbial DNA extractions were performed using the DNeasy
PowerLyzer PowerSoil Kit (QIAGEN, Hilden, Germany)
according to manufacturer’s instruction. Briefly, 0.150 g caecum
samples were added into the bead tube, 750 µl of bead solution
and 60µl solution C1 were added, mixed, and incubated (10min,
70◦C). A mechanical lysis step was added and done with the
FastPrep-24 Homogenizer (MP, 6.5 m/s, 45 s). The purification
was done according to the manufacturer’s protocol. The DNA
was eluted with 100 µl of solution C6, centrifuged (10,000 × g,
1min), and UV light irradiated (30min) to minimize foreign
DNA. Negative kit, as well as PCR controls were performed
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using only water and elution buffer (solution C6). In addition,
mock communities were run along as a standard and a control
for contamination.
Library Preparation for Sequencing on MiSeq Illumina
Platform
The V4 of the 16S rRNA gene was amplified using primer
taken from Caporaso et al. (36). The amplification was done
using the Platinum SuperFi PCR Master Mix (Thermo Fisher
Scientific, Carlsbad, USA.). Each PCR reaction results in a total
of 25 µl reaction solution composed of 2x SuperFi PCR Master
Mix, 1.25 µl of 10 pmol forward and reverse primer, and a
maximum of 10µl DNA per reaction. After mixing the solutions,
the following thermocycler conditions were run: 2min at 98◦C,
25 cycles with 10 s at 98◦C, 10 s at 55◦C, and 30 s at 72◦C followed
by a final 5min step at 72◦C.
After amplification the PCR products were confirmed to be
of the right size on a 1% agarose gel. The products were purified
using AMPure XP DNA beads (Beckman Coulter, Brea, USA.).
The index and adapter ligation PCR was done using the Nextera
XT Index Kit V2 Set A and B (Illumina, San Diego, USA) and
performed according to the manufacturer’s protocol.
The PCR conditions were set as follow: 3min at 95◦C, 8 cycles
with 30 s at 95◦C, 30 s at 55◦C, and 30 s at 72◦C plus a final step
for 5min at 72◦C. Quality and quantity control of purified PCR
products were done using the Qubit instrument (Thermo Fisher
Scientific, Waltham, USA) and the 2100 Bioanalyzer instrument
(Agilent Technologies, Santa Clara, USA). All samples were
diluted to the same molarity (2 nM), pooled, spiked with an
internal 15% PhiX control, and paired-end sequenced on the
MiSeq Illumina platform using a Nextera V2 cartridge and
chemistry with 500 cycles.
Bioinformatics Microbiota Workflow
MiSeq Software v3.0 was used to split the sequences by barcode
and to generate the fastq files. The microbiota analysis was
done following the MiSeq SOP (https://www.mothur.org/wiki/
MiSeq_SOP, date accessed: 2018-06-01) using Mothur (version
1.36.1) (37).
The paired end reads were joined, and the primer sequences
were removed. We filtered for the expected amplicon length,
and removed reads with either ambiguous base calls or
with homopolymers longer than eight nucleotides. Duplicate
sequences were merged. The unique reads were aligned against
the SILVA-bases bacterial reference alignment (38). Nucleotides
outside the expected alignment region were trimmed. Reads
with a difference of up to two nucleotides were merged during
pre-clustering. Chimeric reads were removed using the Mothur
implementation of the uchime algorithm. After chimera removal
the taxonomy was assigned, and non-bacterial reads were
removed. The operational taxonomic units (OTUs) were created
using the cluster split method of Mothur. After clustering, we
reassigned the taxonomy and removed low abundance OTUs.
Principal coordinates analysis (PCoA) was performed to
determine the similarity of samples to each other based on
the unweighted unifrac (39) distance. Confidence intervals were
calculated using the R package ellipse. Differentially abundant
OTUs between groups were computed using linear discriminant
analysis (LDA) effect size (LEfSe) (40).
Data Analysis
For statistical analysis Prism 6 was used (GraphPad Software,
San Diego). Samples were categorized by Kolmogorov-Smirnov
normality test (threshold at p = 0.05) to one of the following
distributions: (A) Gaussian, (B) log-normal, (C) other non-
Gaussian. Statistical significance (p ≤ 0.05) was then analyzed
by appropriate tests as stated in the respective figure legends.
For microbiota analysis, the linear discriminant analysis effect
size (LEfSe) implementation of Mothur was used to compare the
OTUs of the different groups.
RESULTS
PGLYRP4KO Mice Have an Enhanced
Bacterial Clearance
It has been previously published that PGLYRP4 has an
antibacterial function against various gram-positive and gram-
negative bacteria, and recombinant human PGLYRP4 protected
mice from Staphylococcus aureus-induced lung infection (11).
Interestingly, PGLYRP4KO mice, which were transnasally
infected with 105 cfu S. pneumoniae per mouse, had a significant
decrease in bacterial loads by approximately two-log in the lung
(Figure 1A), approximately three-log in the blood (Figure 1B),
and a tendency for a small decrease in the spleen (Figure 1C)
compared to WT mice 48 h post infection. Furthermore, less
PGLYRP4KO mice showed bacteremia (Figure 1D), and they
also showed lower clinical scores (Figure 1E) compared to
WT mice.
Streptococcus pneumoniae-Infected
Lungs of PGLYRP4KO Mice Display
Stronger Inflammation and Increased Cell
Counts in vivo
Histological examination revealed increased tissue damage as
displayed by larger areas of perivascular (left and center panel),
interstitial and alveolar (right panel) necrosis and hemorrhage
accompanied with increased immune cell infiltration, as well as
prominent perivascular edema (left and center panel) in infected
PGLYRP4KO vs. WT mice (Figure 2A).
A quantitative digital image analysis resulted in significantly
more expansive affected/inflamed lung areas (Figure 2B) in
infected PGLYRP4KO vs.WTmice with significantly higher total
cell counts (Figure 2C).
By histochemical immuno-staining and quantification by
digital image analyses we could detect an increase in the
number of T cells (Figure 2D, CD3+), B cells (Figure 2E,
CD45R+), and neutrophils (Figure 2F, NE+) but not in the
monocyte/macrophage population (Figure 2G, CD68+) in the
lungs of infected PGLYRP4KO mice compared to infected
WT mice.
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FIGURE 1 | Lower bacterial burden in lungs and blood of PGLYRP4KO mice. Mice were infected with S. pneumoniae (NCTC 7978, 105 cfu) for 48 h and (A) the
lungs, (B) the blood, and (C) the spleens were analyzed for the bacterial load. In addition, (D) the number of bacteremic mice and (E) the clinical score (min.: 1, max.:
12) was assessed. A total of 19 mice were used in (A–D) and 23 mice (including 4 mice from histological analysis) in (E). In (A–C), the bars represent the means ±
SEMs and in (E) the mean + SEM is given. The dotted lines represent the lower limit of detection (LLOD). Undetected samples were set to half of the LLOD for
statistical purposes. Statistical analysis: (A–C) and (E): Student’s t-test on logarithmic data and (D) Chi²-test; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, nsp ≥ 0.1.
FIGURE 2 | Histopathological and digital image analyses of infected WT and PGLYRP4KO mouse lungs. The lungs of infected (S. pneumoniae, NCTC 7978, 105 cfu,
48 h post infection) mice were harvested, fixed in formalin, and embedded in paraffin. Afterwards, 2µm sections were prepared and stained with (A–C) hematoxylin
and eosin for histopathological analyses or (D–G) CD68, NE, CD45R, or CD3 antibodies for quantification of immune cell populations in the lung. (A) Representative
images for WT and PGLYRP4KO are shown (n = 3–4 per group). Bar (left panel), 100µm. Bar (center and right panel), 50µm. The panels are showing representative
areas of the perivascular area (left and center) and the alveolar compartment (right panel). Quantitative digital image analysis on digitalized whole lung sections was
performed by using an adapted GENIE pattern recognition algorithm and v9 nuclear count algorithm and (B) the percentages of affected/inflamed lung areas and (C)
total cell counts in the lungs were assessed. Further, total cell count per lung area of (D) CD68+ (macrophages/monocytes), (E) NE+ (neutrophils), (F) CD45R+ (B
cells), and (G) CD3+ (T cells) were digitally quantified. Values are expressed as means + SEMs. Statistical analysis: Student’s t-test: **p ≤ 0.01 vs. infected WT.
Pglyrp4 Expression Is Reduced in Alveolar
Epithelial Cells and Induced in
Macrophages by S. pneumoniae
To investigate possible underlying mechanisms for the lower
bacterial burden as well as the higher inflammation and cell
recruitment in the lungs of PGLYRP4KO mice, we first analyzed
the expression of Pglyrp4 in resident primary lung cells and
recruited innate cell populations. The relative expression of
Pglyrp4 was determined in alveolar epithelial cells (AECs),
alveolar macrophages (AM8s), and bone marrow-derived
neutrophils (PMNs). Pglyrp4 was found to be expressed in all
tested cell types (Figure 3A). Upon infection with pneumococci,
Pglyrp4was significantly downregulated to approximately 40% of
the untreated control value in AEC and increased significantly
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FIGURE 3 | Differential regulation of Pglyrp4 and candidate gene expression in primary cells. The Pglyrp4 expression was measured by qPCR in in vitro-stimulated (S.
pneumoniae D39, MOI 1, 6 h) vs. unstimulated WT primary (A) alveolar epithelial cells (AECs), alveolar macrophages (AM8s), and bone marrow-derived neutrophils
(PMNs). (B) The expression of the tight junction genes Cldn18, F11r, and Cdh1 in PGLYRP4KO vs. WT AECs as well as (C) complement C3, (D) Ifng, and (E) Ifngr1 in
PGLYRP4KO vs. WT AECs, AM8s, and PMNs was analyzed after infection (S. pneumoniae D39, MOI 1, 6 h). Relative expression was calculated by the 11CT
method with Gapdh as the housekeeping gene and uninfected WT cells as the control. Values are expressed as means + SEMs (n = 3–5). The dotted line represents
the level of uninfected WT cells. Statistical analysis: Student’s t-test: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, nsp ≥ 0.1 vs. untreated control.
4-fold in AM8s (Figure 3A). However, in PMNs the expression
of Pglyrp4 did not change (Figure 3A).
Next, we used global gene expression microarrays to get
preliminary data on regulated genes in AM8s (Figure S1)
and AECs (Figures S2–S5) for elucidating a possible
mechanism of the improved bacterial clearance and increased
lung damage in infected PGLYRP4KO mice compared to
WT controls.
The microarray of AM8s did not reveal any candidate genes
(Figure S1). In contrast, the complement component C3, the
gamma interferon (Ifng) (Figure S4) as well as the tight junction
genes Clnd18, F11r, and Cdh1 (Figure S5), had higher expression
levels in AECs from PGLYRP4KO compared to WT mice.
Therefore, these genes were analyzed by qPCR in AECs. All these
genes were significantly upregulated in AECs of PGLYRP4KO
compared to WT mice (Figures 3B–E). To show the exclusive
role of AECs, C3, Ifng, and Ifngr1 were also analyzed in AM8s
and PMNs. No major changes in the expression levels of these
genes were detected (Figures 3C–E).
PGLYRP4-Deficiency Leads to a
Pro-inflammatory Cytokine Response
Since we observed more inflamed lung tissue in the
histopathological analysis, we were interested if this correlated
with higher levels of pro-inflammatory cytokines released by
resident and recruited cells in the lung. Therefore, we analyzed
the pneumococci-dependent cytokine response in different
primary cell types.
As expected, the stimulation with S. pneumoniae induced
a strong cytokine response in WT AECs, AM8s, and PMNs
(Figures 4A–H). Interestingly, the pneumococci-dependent
cytokine response was altered by PGLYRP4KO in all tested
cell types.
In AECs we found a tendency for an increase of
TNF-α (Figure 4A) andKC (Figure 4B) in infected PGLYRP4KO
compared to infected WT cells, while IL-1β was not detectable
(data not shown).
In AM8s the pneumococci-dependent IL-1β secretion was
significantly enhanced (Figure 4C), the TNF-α response was not
altered (Figure 4D), and the KC production was significantly
reduced (Figure 4E) in infected PGLYRP4KO compared to
infected WT cells.
In the bone marrow-derived PMNs significantly greater
amounts of IL-1β (Figure 4F), TNF-α (Figure 4G), and KC
(Figure 4H) were detectable in the S. pneumoniae-stimulated
PGLYRP4KO compared to the WT cells.
Improved Activation of PMNs Caused by
Pro-inflammatory Cytokines in
PGLYRP4KO AECs
Because there were less bacteria in the lungs and the blood,
an increased pro-inflammatory cytokine release by PMNs, and
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FIGURE 4 | Enhanced pro-inflammatory cytokine release in PGLYRP4KO vs. WT cells. Different cell types were analyzed 6 h after in vitro-stimulation with S.
pneumoniae (D39; MOI 1). In alveolar epithelial cells from either WT or PGLYRP4KO (KO) mice (A) TNF-α, (B) KC, in alveolar macrophages (C) IL-1β, (D) TNF-α, and
(E) KC, as well as in bone morrow-derived neutrophils (F) IL-1β, (G) TNF-α, and (H) KC were analyzed. Values are expressed as means + SEMs (n ≥ 3 as indicated in
the graphs). Statistical analysis: One-way ANOVA with Holm-Sidak correction for multiple comparisons: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 vs.
untreated control. #p ≤ 0.05, ##p ≤ 0.01, ####p ≤ 0.0001 vs. infected WT. KO = PGLYRP4KO.
more recruited PMNs detected, as shown by lung histology in
PGLYRP4KO vs. WT mice, we hypothesized that the recruited
PMNs might be more activated. To corroborate this, WT and
PGLYRP4KO PMNs were analyzed in vitro for their killing
capacity (Figure 5). There was no difference in the efficiency of
WT and PGLYRP4KO PMNs to kill S. pneumoniae (Figure 5B).
Since AECs are in the first line of defense in the lung,
show higher expression of interferon-related genes, Ifng,
complement factors, and might release more pro-inflammatory
cytokines, they could be responsible for a hypothesized higher
activation of recruited PMNs. To analyze this, sterile-filtered
supernatant from primary AECs infected with S. pneumoniae
was used to pre-incubate PMNs before the killing assay was
performed (Figure 5).
There was an enhanced clearance by WT and PGLYRP4KO
PMNs stimulated with the respective AEC supernatant
compared to naive cells, whereas the clearance was higher
in PGLYRP4KO PMNs which were pre-incubated with the
supernatant from PGLYRP4KO AECs compared to WT
PMNs (Figure 5B).
To prove that the effect was due to the phenotype of the AECs
and not to the genotype of the PMNs, a crossover experiment
was done. For this purpose, WT PMNs were pre-incubated with
the AEC supernatant from PGLYRP4KO cells and vice versa. As
expected, there was an enhanced killing in both conditions with
a higher clearance in WT PMNs stimulated with PGLYRP4KO
AEC supernatant (Figure 5B).
Analysis of the Caecal Microbiome From
WT and PGLYRP4KO Mice
It was previously reported that the gut microbiota is altered in
PGLYRP4KO mice, and that some altered bacteria species from
this microbiota can affect the outcome of disease in PGLYRP4KO
mice (19, 21). Therefore, we examined the caecal microbiota by
16S rRNA gene amplicon-sequencing between S. pneumoniae-
infected and uninfected mice.
Analysis of taxonomic abundance showed well-known
gut-related bacteria such as Lachnospiraceae, Bacteroidales
S24-7, Lactobacillaceae, Rikenellaceae, and Ruminococcaceae
(Figures 6A,B) among the top 10 families. Beta diversity analysis
by principal coordinate analysis (PCoA) grouped WT and
PGLYRP4KO into two clusters (Figure 6C) which could be
significantly distinguished by OTUs using linear discriminant
analysis (LDA) score plots (Figures S6, S7).
Next, we were interested if these changes in the microbiota
could influence the outcome of pneumococcal lung infection.
Therefore, we set up a cohousing experiment to transfer
the microbiota from WT mice into germfree WT mice
(WT→GF) and from PGLYRP4KO mice into germfree WT
mice (KO→GF).
The microbiota transfer from both groups, non-infected and
infected, WT into WT→GF mice and from PGLYRP4KO into
KO→GFmice resulted in a comparably stable microbiota profile
which was indicated by a similar relative abundance pattern of
the top 10 families (Figures 6A,B).
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FIGURE 5 | Killing of S. pneumoniae by neutrophils is enhanced by supernatants of PGLYRP4KO alveolar epithelial cells. Neutrophils were isolated from the bone
marrow and their capacity for killing of S. pneumoniae D39 was analyzed in several conditions. (A) Scheme of the experimental setting and (B) surviving bacteria after
incubation with PMNs or activated PMNs (D39, MOI 100, 1 h). First, WT and PGLYRP4KO PMNs were analyzed alone. Second, WT and PGLYRP4KO PMNs were
pretreated with respective sterile filtered AEC supernatants, which were infected with S. pneumoniae (D39, MOI 1, 16 h). Third, a cross-over experiment was
conducted using WT PMNs pretreated with PGLYRP4KO AEC supernatant and PGLYRP4KO PMNs pretreated with WT AEC supernatant. Values are expressed as
means + SEMs (n = 3 for PMNs alone and n = 5-6 for all other experiments). Statistical analysis: One-way ANOVA with Holm-Sidak correction for multiple
comparisons on logarithmic data: *p ≤ 0.05, ***p < 0.001, nsp ≥ 0.1. KO = PGLYRP4KO.
Transfer of the PGLYRP4KO Microbiota
Into Germfree WT Mice Enhances
Clearance of S. pneumoniae in the Lungs
and Reduces Clinical Score
We saw a successful and stable transfer of microbiota into the
germfree WT mice. Increasing data implicate an influence of gut
microbiota on distant organs such as the brain and the lung via
SCFA (24, 27, 41). Therefore, we next analyzed the bacterial loads
of infected cohoused mice.
Infection of WT, PGLYRP4KO, and former germfree mice
colonized with wildtype (WT→GF), or PGLYRP4KO (KO→GF)
microbiota revealed that the WT→GF and KO→GF mice had
higher bacterial loads (Figures 7A–C), higher clinical scores
(Figure 7D), and slightly higher abundance of bacteremia
(Figure 7E) compared to WT and PGLYRP4KO mice.
Comparing WT vs. PGLYRP4KO and WT→GF vs. KO→GF
mice, it was evident that KO→GF mice showed the same
reduction in bacterial loads in lung (Figure 7A), blood
(Figure 7B), and spleen (Figure 7C), clinical score (Figure 7D),
and bacteremia (Figure 7E) than PGLYRP4KO mice. However,
mean bacterial load in blood between WT and PGLYRP4KO
mice shows only a minor difference, which was due to a small
proportion of outliers. Median bacterial loads (not shown) and
proportion of bacteremia (Figure 7E) is still much lower in
PGLYRP4KO vs. WT mice.
DISCUSSION
We report here an unexpected observation of improved bacterial
clearance, hallmarks of pulmonary barrier protection, and
enhanced inflammation in mice lacking the host defense factor
PGLYRP4. Peptidoglycan recognition proteins have been known
about for the last two decades (7, 8). During this time,
they were studied extensively in drosophila (9) but also in
mammalians including mice and humans (10), and functions, as
well as mechanisms of action were characterized in insects and
mammalians (9, 10, 42–44).
Mammalian PGLYRP4 was shown to be antibacterial in
vitro for several gram-positive and gram-negative bacteria
including Bacillus subtilis, Escherichia coli, Lactobacillus
acidophilus, Listeria monocytogenes, Proteus vulgaris, Salmonella
enterica, and Staphylococcus aureus (11, 12). Because of
this broad spectrum of known antibacterial activity, but
unknown activity against S. pneumoniae, we investigated the
in vivo effects of PGLYRP4 in a PGLYRP4-deficient mouse
pneumonia model.
Interestingly, we observed an approximately 1.5, 3, and 0.5
log lower bacterial burden in the lungs, blood, and spleens of
infected PGLYRP4KO compared to WT animals, respectively.
This is unexpected in so far as silencing an antibacterial protein
should lead to a higher bacterial burden. Therefore, other
mechanisms than direct antibacterial functions vs. S. pneumoniae
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FIGURE 6 | Stable transfer of WT and PGLYRP4KO microbiota into germfree WT mice, and distinct microbiome differences between WT and PGLYRP4KO mice. In
(A,B) the top 10 families found in caecum from PGLYRP4KO and WT mice are listed. Left: cumulative bar charts comparing relative family abundances. Right:
variation in relative abundance of each family. The red line shows cut off for noise. Families not in the top 10 by relative abundance are categorized as other families.
(A) Uninfected samples and (B) samples infected with S. pneumoniae (NCTC 7978, 105 cfu, 48 h). (C) PCoA plot based on unweighted UniFrac distances for
PGLYRP4KO and WT samples infected S. pneumoniae and uninfected controls. Green and red circle mark the 95% confidence interval for PGLYRP4KO and WT
samples.
must be responsible for the lower bacterial burden. It is
known that PGLYRP4 has anti-inflammatory properties (18,
19), and therefore, the PGLYRP4-deficiency could lead to
higher inflammation.
Inflammatory processes are essential for the clearance of
bacteria by mechanisms such as recruitment and activation
of phagocytes (2, 45), but also lead to tissue damage
and hyperinflammation (46–48). Patho- and immunohistology
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FIGURE 7 | Germfree WT mice with PGLYRP4KO microbiota have an enhanced bacterial clearance in the lungs and lower clinical scores than WT→GF mice.
Germfree WT mice were cohoused together with either WT or PGLYRP4KO mice from age 3-4 weeks until an age of 9-10 weeks. Then, all animals were infected with
S. pneumoniae (NCTC 7978, 105 cfu, 48 h) and (A) the lungs, (B) the blood, and (C) the spleens were analyzed for the bacterial burden. (D) The clinical score (min.:
1, max.: 12) and (E) the percentage of bacteremic mice were assessed. In (A–C) the bars represent the means ± SEMs and in (D) the mean + SEM is given. A
combined analysis with all animals used in this study was done. In (A–C) and (E) 29 WT and PGLYRP4KO mice and each 10 WT→GF and KO→GF mice were used.
In (D) additionally four WT and PGLYRP4KO mice were analyzed. Statistical analysis: (A–D) One-way ANOVA with Holm-Sidak correction for multiple comparisons on
logarithmic data, and (E) Chi²-test with number of animals; *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001, nsp ≥ 0.1. KO = PGLYRP4KO.
revealed higher inflammation in the lungs and more infiltrating
cells, including PMNs, T, and B cells.
Higher inflammation might be due to a higher secretion of
pro-inflammatory cytokines from PMNs, but AM8s or AECs
could also play a role as seen by our in vitro assays. In addition, we
showed that PMNs kill more pneumococci, if they are activated
by soluble factors from PGLYRP4KO vs. WT AECs. This might
be partly due to higher expression of complement (C3), Ifng, and
IFN-regulated and—associated genes, as revealed by microarray
and qPCR experiments.
Complement is essential for the elimination of S. pneumoniae,
and a loss of C3 leads to invasive and recurrent infections
(49). However, S. pneumoniae uses defense mechanisms
against complement. Therefore, an increase might only have
minor effects on direct killing (50). IFN-γ, like TNF-α,
IL-6, and KC, is a known activator of PMNs (51–53) and
therefore, might act synergistically with complement and other
soluble factors for the recognition and better clearance of
pneumococci by PMNs.
In addition to the enhanced clearance, we showed higher
expression of tight junction genes in infected AECs from
PGLYRP4KO compared to WT mice. A down-regulation of
tight junction proteins is associated with a higher translocation
of S. pneumoniae through the epithelial barrier (54). Therefore,
an induction in tight junction genes indicating a protective
effect on pulmonary barrier integrity and might contribute
to a reduction of bacteremia in the PGLYRP4KO mice. This
might also be modulated partly by IFN-γ, as IFN-γ was
shown to have a positive effect on the lung barrier function
(55). However, there are only a few reports considering
IFN-γ in pneumococcal infection and barrier function
in bacterial diseases. Therefore, these results should be
taken with care.
Up to this point, it is unclear how PGLYRP4 is modulating
the gene expression and pro-inflammatory cytokine release, and
if this pro-inflammatory cytokine release is indeed responsible
for the better clearance of pneumococci in PGLYRP4KO
mice. Recently, several studies revealed that the gastrointestinal
microbiota play an important role in the immune response,
and the host defense against respiratory diseases underlining the
importance of the gut-lung axis related microbiota interactions
(25, 56). Schuijt et al. investigated the outcome between gut
microbiota-depleted mice and a control group after pulmonary
infection with S. pneumoniae. In this work, the authors
could show that mice with gut microbiota-depletion are
more susceptible to infection with S. pneumoniae, showing a
higher mortality rate and a higher bacterial burden in the
lung (25).
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Commensal bacteria help to maintain homeostasis of the
host, including the immune response. Some commensal bacteria
such as Bacteroidetes have shown immunomodulatory effects by
producing metabolites, e.g., SCFA including acetate, propionate,
and butyrate (27).
Those produced SCFA are able tomigrate into distant mucosal
sites via the blood stream (27), where they can have a systemic
influence on distant sites such as the lung to contribute to
immunity and health (57).
PGLYRP4KO mice have a lower abundance of Bacteroidetes
in the gut, resulting in a lower amount of SCFA producing
bacteria, which may result in less anti-inflammatory effects.
These observations lead to the hypothesis that the PGLYRP4KO
mice have a more pro-inflammatory primed immune system
caused by the gut microbiota.
Among Firmicutes, several Lactobacilli species are known to
be probiotic and show protective behavior during diseases like
urogenital infection caused by Staphylococcus aureus (58) and
Salmonella enteritidis infection (59). In addition to protective
effects, Lactobacilli species also possess immunomodulatory
activities (60). A study investigated the immunomodulatory
effects of two Lactobacillus rhamnosus strains during infection
with S. pneumoniae (61). Only one strain was associated
with an increase in Th1 and Th2 cytokines, and a decrease
of bacterial burden when examining BAL samples, indicating
the immunomodulatory effects are Lactobacillus rhamnosus
strain specific.
In addition, different Lactobacilli species (e.g., Lactobacillus
reuteri and Lactobacillus crispatus) of the gastrointestinal tract
revealed their ability to promote resistance to lung infection
through NOD2 signaling and GM-CSF release (62). Our
microbiota analysis indicates that Lactobacillus (OTU0002 and
OTU00029) is significantly more abundant in the gut of infected
PGLYRP4KO compared to WT mice, which might explain the
pro-inflammatory phenotype of PGLYRP4KO mice.
Furthermore, we could illustrate that the transfer of the
PGLYRP4KO microbiota into germfree WT mice (KO→GF) is
sufficient to improve pneumococcal clearance, and significantly
reduces the clinical disease score. However, there are
discrepancies between the original experiments with WT
vs. PGLYRP4KO mice and the cohousing experiments. Mean
blood cfu’s, and the corresponding statistical analysis, are
highly influenced due to outliers in the PGLYRP4KO group.
However, the overall interpretation does not change because the
PGLYRP4KO mice still show less bacteremia compared to the
WT mice.
We therefore conclude that intestinal microbiota shapes
and influences the lung immunity. This might be via SCFA
release and microaspirated bacteria from the gut which finally
contributes to lung immunity to support better pathogen
clearance in PGLYRP4KO mice. However, microbiotal changes
have to be carefully considered in the disease setting, because
we have seen a more pro-inflammatory gut microbiome
and a more pro-inflammatory lung milieu. This might be
disadvantageous in some diseases like COPD or Crohn’s
disease but beneficial in other settings like S. pneumoniae
lung infection.
Further studies will be needed to establish the precise mode
of action in which PGLYRP4 shapes the microbiota, how the
microbiota mediates its effects and to which extent these effects
can be transferred into germ-free mice.
Taken together, our results indicate that lung epithelial cells
not only function as barriers and sensors of invading bacteria,
but also are capable of activating professional phagocytes for
pathogen killing. Furthermore, the microbiota are highly capable
of modulating the immune system. Through a loss of PGLYRP4,
the (gut) microbiota is altered and this in turn influences gene
expressions, pro-inflammatory cytokine release, and immune
functions in the lungs to help combat S. pneumoniae infections.
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